Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study

BACKGROUND: Recent studies indicate the benefit of treatment with osimertinib over that with conventional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for untreated EGFR-mutated non-small cell lung cancer (NSCLC). Cobas ver2 is the only companion diagnostic method for det...

Full description

Saved in:
Bibliographic Details
Published in:BMC Cancer
Main Authors: Kogo, Mariko, Fujimoto, Daichi, Hosoya, Kazutaka, Nagata, Kazuma, Nakagawa, Atsushi, Tachikawa, Ryo, Yamashita, Daisuke, Kitamura, Yuka, Imai, Yukihiro, Tomii, Keisuke
Format: Artigo
Language:Inglês
Published: BioMed Central 2020
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006383/
https://ncbi.nlm.nih.gov/pubmed/32028905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6603-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items